Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Wharton, Sean; Blevins, Thomas; Connery, Lisa; Rosenstock, Julio; Raha, Sohini; Liu, Rong; Ma, Xiaosu; Mather, Kieren J.; Haupt, Axel; Robins, Deborah A.; Pratt, Edward John; Kazda, C.; Кониг, Маниге

doi:10.1056/nejmoa2302392

Cited by 131 publications

(53 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, at doses from 12 to 45 mgÁday À1 , was associated with weight reduction exceeding 10% at 36 weeks on average in patients with obesity without diabetes. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists (Wharton, et al, 2023).…”

Section: Central Effects Of Incretinsmentioning

confidence: 70%

Newer pharmacological interventions directed at gut hormones for obesity

Camilleri,

Acosta

2023

British J Pharmacology

View full text Add to dashboard Cite

The objective is to review the newer pharmacological interventions for obesity, specifically single, dual, and triple incretin receptor agonists that are either available or in the pipeline for treatment of obesity. The three incretin receptor targets are glucagon like peptide‐1 (GLP‐1), glucose‐dependent insulinotropic peptide (GIP), and glucagon. There are several approved single or dual incretin agonists which are administered subcutaneously daily (e.g., liraglutide) or weekly (e.g., semaglutide, dulaglutide, and exenatide QW), and experimental dual or triple incretin agonists. Other analogs of amylin, peptide YY, and oxyntomodulin, as well as a combination GLP1R agonist and GIPR antagonist are also being developed. Oral semaglutide (administered daily) is approved for type 2 diabetes and is on track for regulatory review for obesity. The review includes specifically perspectives on the effects of these mechanisms and pharmacological agents on gastric emptying which contribute to satiation and weight loss, in addition to the established evidence on effects on central mechanisms controlling appetite. In the future, it is anticipated that small molecule GLP‐1 receptor agonists (e.g., oral danuglipron) will be developed. These pharmacological agents are having significant impact on glycemic control and obesity and their co‐morbidities.

show abstract

Section: Central Effects Of Incretinsmentioning

confidence: 70%

Newer pharmacological interventions directed at gut hormones for obesity

Camilleri,

Acosta

2023

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…One of them is retatrutide, which combines the three hormones GLP‐1, gastric inhibitory polypeptide (GIP) and glucagon, and which has shown markedly high effectiveness in weight reduction 33 . Another drug is orforglipron, which is administered orally and may lead to improved outcomes given its ease of administration 34 . Tirzepatide, combining GLP‐1 and GIP, is already marketed in the United States for people with diabetes 27…”

Section: Discussionmentioning

confidence: 99%

Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures

Guy,

Azab,

Liberty

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimTo identify the sociodemographic, clinical and laboratory determinants relating to patient adherence to liraglutide treatment among individuals with overweight or obesity.MethodsWe retrospectively analysed patients with overweight or obesity who were treated with liraglutide between 2019 and 2022. Over a 6‐month follow‐up period, measurements of body mass index, sociodemographic characteristics, clinical and laboratory data, and prescription records for liraglutide were collected. Treatment adherence was assessed using the proportion of days covered (PDC) measure, with a PDC ≥80% indicating high adherence.ResultsThe study population included 1890 participants (78.1% female, mean age 46 ± 12 years). At the end of the follow‐up period, 84.9% of the participants exhibited low adherence to liraglutide treatment. Adherence to treatment improved with age (p = 0.04, odds ratio [OR] 1.013, confidence interval [CI] 1.001–1.025). Significant weight loss during treatment increased the likelihood of high adherence (p < 0.001, OR 1.251, CI 1.167–1.341). Individuals with a higher socioeconomic status displayed greater adherence (p = 0.023, OR 1.906, CI 1.091–3.328). Greater adherence was also seen in non‐smokers (p = 0.047, OR 0.725, CI 0.528–0.996).ConclusionsOnly 15.1% of study participants exhibited high adherence to treatment (PDC ≥80%) after 6 months of follow‐up. Further research is needed to explore approaches to enhance adherence to liraglutide, including strategies to educate and support patients in their efforts to achieve and maintain weight loss with the use of this drug.

show abstract

“…Other drugs in this class, such as tirzepatide, orforglipron and retatrutide, have also shown promising weight loss in clinic trials, but are not yet available for weight loss in the UK. Orforflipron is available as an oral preparation, in contrast with most other drugs in this class which are injectables (Jastreboff et al, 2023;Wharton et al, 2023).…”

Section: Glp-1 Receptor Agonistsmentioning

confidence: 99%

Management of obesity: Going beyond eating less and moving more

Podlasek

2023

InnovAiT: Education and inspiration for general practice

View full text Add to dashboard Cite

Overweight and obesity are defined as abnormal or excessive adipose tissue accumulation that results in a risk to health. This is caused not simply by poor lifestyle, but rather a complex interplay of health inequalities, genetic inheritance, as well as social and environmental factors. Excess weight significantly increases the risk of chronic illnesses, including cardiovascular diseases, diabetes, musculoskeletal disorders, and various types of cancer. Individuals with a body mass index (BMI) of 30–35 kg/m2 experience an average reduction in life expectancy of 2–4 years and for those with a BMI of 40–50 kg/m2, the decrease in life expectancy ranges from 8–10 years. Experts predict that by 2030, the UK will see 11 000 000 more adults affected by obesity, resulting in a significant increase in the cost of treating obesity-related diseases. This article provides a contemporary overview of obesity understanding and management in adults, including brief interventions, motivational interviewing, as well as pharmacological and surgical options.

show abstract

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Cited by 131 publications

References 19 publications

Newer pharmacological interventions directed at gut hormones for obesity

Newer pharmacological interventions directed at gut hormones for obesity

Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures

Management of obesity: Going beyond eating less and moving more

Contact Info

Product

Resources

About